In-vitro Toxicology Testing Market - Product and Services (Consumables, Assays, Equipment, Software), Endpoint and Test (Genotoxicity, Cytotoxicity), Technology (Toxigenomics, Cell Culture), Method (Ex Vivo, In Silico), Industry – Global Forecast, 2024 - 2032

In-vitro Toxicology Testing Market Size

In-vitro Toxicology Testing Market size reached over USD 1.8 billion in 2023 and is anticipated to register 7.7% CAGR between 2024 and 2032, due to the rising collaboration and partnerships for driving innovation and growth.
 

Leading industry players are joining forces with academic institutions and research organizations to develop advanced testing methodologies and technologies. These collaborations are aimed towards enhancing the accuracy and efficiency of toxicity screening processes for ensuring safer pharmaceutical and chemical product development.
 

These partnerships will continue to foster the development of novel solutions that meet the evolving regulatory requirements and industry needs to ultimately improve public health and safety standards. For instance, in February 2024, Danaher Corporation initiated a strategic collaboration with Cincinnati Children's Hospital Medical Center for focusing on in-vitro toxicology testing. This multi-year partnership aims to enhance patient safety by improving liver organoid technology for drug toxicity screening, potentially saving billions in research productivity.

The cosmetics industry is experiencing a surge in demand due to the ban on animal testing for cosmetics in regions, such as the European Union. This trend is driving cosmetic companies to adopt in-vitro toxicology tests to ensure product safety and compliance with regulations. Lately, more regions are implementing bans on animal testing and necessitating the use of alternative testing methods, such as in-vitro assays.
 

Consequently, the cosmetics industry is increasingly relying on this testing method to meet the regulatory requirements and consumer expectations for cruelty-free products. For instance, in March 2023, local biotech start-up Revivo BioSystems launched a cosmetics testing platform replicating blood flow under the skin. This innovation is encouraging companies to shift from animal testing for aligning with advancements in in-vitro testing methodologies.
 

However, the lack of expertise and the complexity of biological systems may hinder the market growth to some extent. Researchers are continuously grappling with understanding and navigating intricate biological processes. Addressing this challenge would involve training and advancements in technology to enhance expertise and simplify the interpretation of complex biological responses.
 

In-vitro Toxicology Testing Market Trends

The rise in government funding and initiatives are playing a pivotal role in the industry growth. Multiple governments are actively supporting the development and adoption of alternative testing methods through funding programs and regulatory incentives. These initiatives are aimed at enhancing the accuracy, efficiency, and ethical standards of toxicity testing while reducing reliance on animal models. This rising support will drive innovation in the field and lead to the advancement and widespread adoption of alternative testing methods to ensure safer product development across industries.
 

For instance, in June 2023, the Tox21 Consortium prioritized substances for detailed toxicological assessment for identifying mechanisms of action and developing predictive models using in-vitro approaches.
 

In-vitro Toxicology Testing Market Analysis

Based on product and services, the consumables segment is poised for significant growth at 7.8% CAGR from 2024-2032, due to continuous advancements and innovations. Advanced consumables including cell culture media, reagents, assay kits, and plates, play a vital role in facilitating accurate and reliable toxicological assessments. As technology is progressing, the development of consumables with improved sensitivity and specificity is growing for enhancing the efficiency and effectiveness of toxicity testing procedures.
 

Based on endpoint and test, the in-vitro toxicology testing market size from the absorption, distribution, metabolism, and excretion (ADME) segment is predicted to record 7.4% CAGR through 2032. This is due to the rising popularity of in-vitro toxicology testing, particularly in ADME over its traditional counterparts. In-vitro ADME assays are being regarded as cost-effective, quicker, and ethically preferable substitutes to animal experiments. High-throughput screening techniques in ADME testing are gaining traction and empowering researchers to assess vast quantities of compounds with greater efficiency.
 

Based on industry, the in-vitro toxicology testing market from the pharmaceuticals and biopharmaceuticals segment may reach over USD 1.6 billion by 2032. This is majorly propelled by the demand for advanced testing methodologies. Pharma and biopharma sectors are increasingly relying on in-vitro models to assess the safety and efficacy of drug candidates. Continuous R&D efforts are refining these testing approaches and ensuring better predictivity and relevance to human physiology. The pharmaceutical and biopharmaceutical companies are also continuing to invest in testing methods for leveraging emerging technologies, such as organ-on-a-chip models and high-throughput screening platforms to accelerate drug development pipelines and improve patient safety profiles.
 

On the basis of technology, the cell culture segment of the in-vitro toxicology testing market is poised for significant growth at 7.8% CAGR through 2032. This expansion can be ascribed to the rising focus of researchers on continuously refining cell culture techniques to better mimic human physiology and improve the relevance and reliability of test results. Moreover, cell culture methodologies will be advancing further with innovations, such as 3D cell cultures and organoids for offering more physiologically relevant models for toxicity assessment. These advancements will contribute to more accurate predictions of human responses to various substances for enhancing safety evaluations for pharmaceuticals and other products.
 

In terms of method, the market size from the cellular assays segment will exceed USD 1.4 billion by 2032 owing to the emergence of high-content screening (HCS) techniques. HCS, with its automated analysis of multiple cellular parameters is transforming the assessment of cellular responses to toxic substances. Concurrently, genomic and transcriptomic assays are evolving and offering deeper insights into gene expression changes induced by toxicants.
 

North America in-vitro toxicology testing market size accounted for over USD 857 million in 2023 and is predicted to witness 7.8% CAGR through 2032 due to the growing emphasis on environmental awareness and personalized medicine. Stakeholders are increasingly adopting in-vitro testing methods to assess environmental risks and evaluate the toxicity of various compounds. Moreover, personalized medicine initiatives are driving the development of tailored treatments and prompting the need for precise toxicity assessments to ensure patient safety in North America.
 

In-vitro Toxicology Testing Market Share

Key players in the market are leveraging innovative technologies to develop advanced testing methodologies. They are continuously expanding their product portfolios and investing in R&D activities to meet the evolving demands of regulatory compliance and customer needs.
 

In-vitro Toxicology Testing Market Companies

• Abbott Laboratories
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Charles River Laboratories International, Inc.
• Danaher Corporation
• Eurofins Scientific
• Evotec S.E.
• Catalent, Inc.
• Laboratory Corporation of America Holdings
• Merck KGaA
• Quest Diagnostics Incorporated
• SGS Societe Generale de Surveillance SA
• Thermo Fisher Scientific Inc.
   

In-vitro Toxicology Testing Industry News

• In September 2023, Quris-AI extended its collaboration with Merck KGaA Darmstadt. This follows a successful preclinical study assessing Quris-AI’s ability to predict drug toxicity while  enhancing in-vitro toxicology testing.
   
• In February 2023, Evotec announced the relocation of its subsidiary, Cyprotex US, LLC, from Watertown to Framingham, U.S. This strategic move aimed to bolster the capacity of the new facility for enabling quicker turnaround times and supporting Evotec's growth trajectory.
   

In-vitro toxicology testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product and Services

• Consumables
• Assays
  • Bacterial toxicity assays
  • Enzyme toxicity assays
  • Cell-based ELISA and western blots
  • Receptor binding assays
  • Tissue culture assays
  • Others assays 
• Equipment
• Software
• Services

Market, By Endpoint and Test

• Absorption, distribution, metabolism, and excretion (ADME)
• Skin irritation, corrosion, sensitization
• Genotoxicity
• Cytotoxicity
• Ocular toxicity
• Organ toxicity
• Phototoxicity
• Dermal toxicity
• Other endpoints and tests

Market, By Technology

• Cell culture
• High throughput
• Toxicogenomics

Market, By Method

• Cellular assays
• Biochemical assays
• In silico models
• Ex vivo model

Market, By Industry

• Pharmaceuticals and biopharmaceuticals
• Cosmetics and household products
• Food
• Chemicals

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa